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We have developed a therapeutic vaccine consisting of a mixture of lethally-irradiated allo-
geneic cutaneous melanoma cell lines with BCG and GM-CSF as adjuvants. The CSF-470
vaccine is currently being assayed in a Phase II–III trial against medium-dose IFN-α2b.
All vaccinated patients immunized intradermally developed large edematous erythema
reactions, which then transformed into subcutaneous nodules active for several months.
However, vaccine injection sites were not routinely biopsied. We describe the case of a
female patient, previously classified as stage III, but who, due to the simultaneous dis-
covery of bone metastases only received one vaccination was withdrawn from the study,
and continued her treatment elsewhere. This patient developed a post-vaccination nod-
ule which was surgically removed 7 weeks later, and allowed to analyze the reactivity and
immune profiling of the inoculation site. An inflammatory reaction with zones of fibrosis,
high irrigation, and brisk lymphoid infiltration, primarily composed of CD8+ and CD20+
lymphocytes, was observed. There were no remaining BCG bacilli, and scarce CD4+ and
Foxp3+ T cells were determined. MART-1 Ag was found throughout the vaccination site.
CD11c+ Ag presenting cells were either dispersed or forming dense nests. Some CD11c+
cells proliferated; most of them contained intracellular MART-1 Ag, and some interacted
with CD8+ lymphocytes. These observations suggest a potent, long-lasting local inflam-
matory response with recruitment of Ag-presenting cells that incorporate melanoma Ags,
probably leading to Ag presentation to naïve T cells.
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INTRODUCTION
A 45-year-old Caucasian woman (patient #1) underwent resec-
tion on May 2012 of a spontaneously bleeding congenital nevus
in her back. Histological analysis revealed an ulcerated nodular
cutaneous melanoma (CM) with a Breslow thickness of 7.8 mm,
epithelioid and spindle cell morphology, non-brisk immune infil-
tration, and satellitosis. Concurrent adenopathies were detected
in her right axilla; axillary lymph node dissection revealed 4/23
metastatic nodes. After signing informed consent on August 23,
2012, this high-risk patient underwent the routine scanning pro-
cedure of the CASVAC-0401 study; on the basis of a normal
CAT scan on June 28, 2012, and normal laboratory, the patient
was classified as stage III and randomized to the vaccine arm.
The patient only received one dose of vaccine (16× 106 lethally
irradiated allogeneic CM cells, plus 106 cfu of Bacillus Calmette
Guerin (BCG) and 400µg of recombinant human granulocyte
Abbreviations: Ag/Ags, antigen/antigens; APC, Ag presenting cells; BCG, bacil-
lus calmette guerin; CM, cutaneous melanoma; DC, dendritic cells; LN, lymph
node; rhGM-CSF, recombinant human granulocyte macrophage-colony stimulating
factor; s.c., subcutaneous; TLS, tertiary lymphoid structures.
macrophage-colony stimulating factor (rhGM-CSF) in four daily
doses), since already at the first visit (September 03, 2012) she
complained of lumbar and left rib cage pain. Presence of bone
metastases were suspected and were confirmed by a PET scan
(October 03, 2012), which revealed bone metastases at the ninth
left rib, the right acetabulum as well as soft tissue metastases at
the right infra-axillary region. The patient was therefore already
at stage IV of her disease, she was discontinued from the study
and continued appropriate treatment elsewhere. The bone metas-
tases were irradiated, and she started treatment with Vemurafenib
since her tumor had the BRAFV600E mutation. Seven weeks after
the single vaccination, the patient decided to remove her subcuta-
neous (s.c.) vaccination nodule. The patient developed progressive
disease, including brain metastases, and died on January 15, 2014.
Routine analysis of vaccine nodules is not contemplated in the
CASVAC-0401 study; this case offered the possibility to study
the histology of one such nodule and its associated immune
profile. After formaldehyde fixation and paraffin embedding of
the entire sample, the vaccination site biopsy was thoroughly
analyzed. The s.c. nodule was located 2 mm below the epi-
dermis (Figure 1A) and three distinct areas of fibrosis, high
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FIGURE 1 | Histological analysis of CSF-470 vaccination site biopsy
from patient #1. Hematoxylin–Eosin stained sections were examined by
optical microscopy (Olympus BX40, Tokyo, Japan); pictures were acquired
with Olympus Digital Camera DP72 and analyzed with Image J software.
(A) Low magnification image of the granulomatous nodule distinguished a
fibrosis zone (I), a highly vascularized zone (II), and a brisk-infiltrated with
inflammatory cells zone (III). (B) Zone (II), in detail, showing lymphocytes
and polymorphonuclear cells. (C) Zone (III) showing dense nested structures
with a polynuclear cell (inset). (D) Ziehl–Neelsen staining revealed absence
of BCG bacilli in the vaccine site. (E) A positive control for bacilli staining is
shown (bowel tuberculosis). Bars=2 mm (A); 50µm (B–E).
vascularization, and brisk lymphoid infiltration could be distin-
guished (Figure 1AI–III). Lymphocytes and polymorphonuclear
cells were distributed around vessels (Figure 1B). Dense nested
structures comprised of macrophages, histiocytes and polynu-
clear cells, typically found in inflammatory processes includ-
ing responses to BCG, were observed in the highly infiltrated
zone (Figure 1C). BCG was rapidly cleared from the site, since
no remaining bacilli were detected by Ziehl–Nielsen staining at
the vaccination site (Figures 1D,E). Immune profiling analysis
revealed brisk CD8+ and CD20+ lymphocyte infiltration, non-
brisk CD4+, and scarce Foxp3+ T cells infiltration (Figures 2A–
D,G). MART-1 antigen (Ag), derived from the vaccine, was found
throughout the inflammatory focus (Figure 2E). Brisk infiltra-
tion of CD11c+ Ag-presenting cells (APCs) was also observed;
these cells were either dispersed in the dermis or assembled in
multiple dense nested structures (Figures 2F,G). Further analysis
FIGURE 2 | Immune profiling and MART-1 distribution in CSF-470
vaccination site biopsy from patient #1. Formalin-fixed,
paraffin-embedded tissue sections were stained with appropriate
antibodies, amplified with avidin-biotin-peroxidase (ABC) system
(Vectastain, Vector Labs), and revealed with 3,3′-diaminobenzidine. Brisk
CD8+ and CD20+ lymphocyte infiltration was observed in zones (II, III), with
scarce CD4+ or Foxp3+ infiltration (A–D). Expression of MART-1 Ag was
observed throughout the inoculation site (E). CD11c+ cells were observed
in dense nested structures (F). Quantification of the immune infiltrate (n°
cells/mm2 tissue surface, mean±SD, two determinations) (G).
Bars=50µm. Antibodies: CD8 (clone C8/144, Dako, CA, USA), CD20 (clone
L26, Dako), CD4 (clone 1F6, Novocastra, Wetzlar, Germany), Foxp3 (clone
236A/E7, Abcam, MA, USA), MART-1 (clone A103, Dako), CD11c (clone
EP1347Y, Abcam).
revealed that some CD11c+ APCs, both dispersed and nested,
proliferated (Figures 3A,B,G), most had phagocytosed MART-1
Ag (Figures 3C,D,G), and some were surrounded by CD8+
lymphocytes (Figures 3E,F), suggesting local Ag presentation.
The near absence of FoxP3+ lymphocytes also suggests that an
immunogenic environment was created.
BACKGROUND
Cutaneous melanoma is a prototypic immunogenic tumor for
which several immunotherapeutic approaches are currently under
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FIGURE 3 | Analysis of CD11c+ Ag presenting cells in CSF-470 vaccination
site biopsy from patient #1. Tissue sections were stained with appropriate
antibodies, revealed with fluorophore-conjugated secondary antibodies, and
examined by confocal microscopy (LSM 5 Zeiss Pascal, Oberkochen,
Germany). Pictures were acquired with Zeiss LSM Image software and
analyzed with Image J software. Both nested (A) and dispersed (B) CD11c+
cells showed some proliferating Ki-67+ cells. Most CD11c+ APCs incorporated
CM Ag MART-1 [(C–D), inset]. CD8+ lymphocytes were observed surrounding
APCs nests, with some T cells interacting with nested (E) and dispersed
CD11c+ cells (F). Quantification of Ki-67+ and MART-1+ cells in nested and
dispersed CD11c+ cells (mean±SD, three high power fields, two
determinations) (G). Bars=20µm. Antibodies: Ki-67 (clone MIB-1, Dako);
MART-1-AF647 [clone 2A9 (1)]. Fluorophore-conjugated secondary antibodies
(Jackson Immunoresearch).
investigation (2). Therapeutic cancer vaccines are aimed at pro-
moting tumor-specific and long-term immunity. Cancer vaccines
have been assayed using different strategies such as the use of
inactivated whole tumor cells,Ag-specific peptides or purified pro-
teins, among others, in combination with adjuvants to create an
immunogenic microenvironment for Ag presentation and expan-
sion of cytotoxic T lymphocytes (3). The classic paradigm proposes
that following inoculation in the dermis, Ags are incorporated and
processed by APCs, such as macrophages and dendritic cells (DCs),
which then migrate to lymph nodes (LN), where processed Ags are
presented to naïve T lymphocytes (1). However, the vaccination
system of choice, combining suitable Ags, adequate adjuvants, and
an appropriate immunization schedule is a delicate equation that
may give rise to tolerance or immunogenicity. Therefore, dissec-
tion of the events that take place at the vaccination site is important
to unravel the induction of an effective immune response.
We have developed multi-Ag allogeneic vaccines for CM treat-
ment. The CSF-470 vaccine, consisting of four lethally irradiated
allogeneic CM cell lines plus BCG and rhGM-CSF as adjuvants, is
currently being assayed versus medium-dose IFN-α2b (2:1 ratio)
in a randomized open trial (CASVAC-0401) in stages IIB, IIC,
and III post-surgery CM patients in adjuvancy (Clinical trials.gov
NCT01729663). The study has been approved by the Comité de
Etica en Investigación del Instituto Médico Especializado Alexan-
der Fleming, and it has so far recruited 32 patients (21 patients
in the vaccine arm and 11 patients in the IFN-α2b arm). The
rationale for the use of this formulation is to immunize patients
with an inert scaffold that spans a broad repertoire of tumor Ag,
thus counteracting heterogeneity in Ag expression (4). Adjuvant
BCG induces a potent local inflammatory reaction with a TH1-
polarizing immune response and epitope spreading (5); rhGM-
CSF stimulates local attraction of APCs and favors a TH1 response
(6). In a previous Phase I study with escalating GM-CSF dosage,
400µg rhGM-CSF per vaccine was found to be the optimal dose.
The combination was safe and induced a predominantly cellular
immune response (7).
DISCUSSION
The results presented here constitute the first in situ evidence
of the afferent arm of the immune response to our cell-based
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melanoma vaccine. In every patient of the vaccine arm, a three
phase local reaction took place: (i) large erythema (typically 10 cm
diameter) with a smaller edema (typically 3 cm diameter) at the
injection site which started on day 2 and lasted about 5–7 days; (ii)
this local reaction later transformed into an erythematous papule,
which occasionally ulcerated, and lasted several weeks; (iii) the
dermal reaction subsided but a subcutaneous nodule persisted,
lasting several months. Other trials with autologous non-small-
cell lung tumor vaccines and GM-CSF reported development of
erythemas with indurations following immunization, supporting
these findings (8, 9). The histological and immune profiling of the
vaccination site biopsy of patient #1 revealed a potent local inflam-
matory response, including highly irrigated and infiltrated zones.
The CSF-470 vaccine is comprised of allogeneic lethally irradiated
CM cells; thus, a host versus graft rejection reaction is expected at
the vaccination site, fueled by BCG and GM-CSF. Interestingly, we
could detect in situ affluence of CD11c+ APCs that incorporated
MART-1 Ag and interacted locally with CD8+ cells, persisting
for several weeks after vaccination (Figure 3). This suggests that
Ag presentation takes place at the immunization site. Although
the classic paradigm proposes that Ag presentation occurs exclu-
sively in secondary LNs, evidence from afferent lymph vessels
in normal human skin revealed an increased number of mainly
memory/effector CD4+CD45Ro+ T cells and IL-12+ DCs in con-
tact with IFN-α-producing T cells, supporting that T cells may be
stimulated by APCs in peripheral tissues (10). Additionally, tertiary
lymphoid structures (TLS) can arise in non-lymphoid organs dur-
ing chronic inflammation, as seen in autoimmune responses, graft
rejection, atherosclerosis, microbial infection, and cancer (11).
TLS can generate effector and memory T cells that lead to allo-
graft rejection (12). We have described the development of TLS
in mice following repeated immunization with DC loaded with
apoptotic/necrotic B16 melanoma cells, supporting the important
role of local events in the generation of a systemic anti-tumor
immune response (13).
We know from murine models that graft infiltration by host
inflammatory monocytes and DCs is a hallmark of graft rejec-
tion; after which APCs travel to the LNs and cross-prime CD8+
T cells, the main effectors of graft rejection (14). Previous reports
on allogeneic GM-CSF-secreting tumor cell vaccines in patients
with pancreatic adenocarcinoma showed affluence of mononu-
clear and eosinophilic cells at the vaccination site on day 3 and
increased CD3+ cells infiltration on day 7 (15). In other study
with prostate cancer patients, immunization led to recruitment of
CD1a+ DCs, CD68+ macrophages, eosinophils, and neutrophils
4 days following inoculation; CD4+ and CD8+ cell affluence
increased with immunizations (16). Pioneering work from Dra-
noff et al. showed that immunization with lethally irradiated
autologous tumor cells transfected with GM-CSF induced specific
immune responses in several pathologies including CM, leukemia,
and brain cancer (6, 17, 18). Immunization with this formulation
in CM patients revealed intense infiltration with T lymphocytes,
DCs, macrophages, and eosinophils (6). Examination of the vacci-
nation site here described indicates that a potent immune reaction
is taking place, which lasts several weeks, and that it has all the
cellular ingredients that might lead to a positive immune response
against tumor Ags.
CONCLUDING REMARKS
The vaccine inoculation site is the gateway for the induction of
an immune response. In this study, we gained access to a vaccine
site biopsy from a CM patient following a single immunization.
We propose that the generation of an immune response toward
tumor Ags by using allogeneic vaccines involves a potent local
inflammation, driven by allograft rejection, and fueled by BCG and
rhGM-CSF. This would favor a proper immunogenic environment
for APC affluence, which subsequently may interact locally with
Ags or migrate toward peripheral LNs for Ag presentation. Since
the CASVAC-0401 study comprises a total of 13 vaccinations over
a period of 2 years, it will be important to analyze the evolution of
vaccination sites at several time points in an ad hoc Phase I trial.
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